Spots Global Cancer Trial Database for Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
Official Title: A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Patients With Solid Tumors
Study ID: NCT00687934
Conditions
Interventions
Study Description
Brief Summary: An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)
Detailed Description:
Eligibility
Minimum Age: 25 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Premiere Oncology, Santa Monica, California, United States
US Oncology Dayton Oncology and Hematology, P.A, Kettering, Ohio, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
